CHILLY-MAZARIN, France, August 20, 2012 /PRNewswire/ –InGen BioSciences, specialized in the development and commercialization of mono and multiparametric in vitro diagnostic tests announced exclusive …

CHILLY-MAZARIN, France, August 20, 2012 /PRNewswire/ InGen BioSciences, specialized in the development and commercialization of mono and multiparametric in vitro diagnostic tests announced exclusive partnerships with two key in vitro …

SHENYANG, China , Aug. 14, 2012 /PRNewswire-Asia/ — 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, …

EDMONTON, Alberta — Isotechnika Pharma Inc. today announced financial results for the second quarter ended June 30, 2012.

NEW YORK, Aug. 9, 2012 /PRNewswire/ — Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic …

The condition of union Science and Technology Minister Vilasrao Deshmukh, admitted to the Global Hospital here, continues to be critical, an official said, adding his family members have declined permission to issue a medical bulletin about his status.

Novartis AG will fund a $20 million research center at the University of Pennsylvania in a deal in which the drugmaker gains technology that uses manipulated immune-system cells to fight cancer.

A Kentucky pharmaceutical company that's developing a complement inhibitor to regulate the immune system and treat severe asthma and COPD is raising a third round.

Optimer Pharma 's ( OPTR ) second quarter 2012 net loss (excluding special items) of 1 cent per share was narrower than the year-ago loss of 52 cents and the Zacks Consensus loss Estimate of

Optimer second quarter 2012 net loss of 1 cent per share was narrower than the Zacks Consensus loss Estimate of 6 cents per share.